InVivoPlus anti-mouse LAG-3

Catalog number: BP0174_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 3522.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoPlus anti-mouse LAG-3

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Flow Cytometry; Neutralisation/Blocking
Species: Mouse
Host: Rat
Clonality: Monoclonal
Isotype: IgG1 Kappa
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: C9B7W
Related products: 
Related products: Recommended Isotype Control(s): InVivoPlus rat IgG1 isotype control (anti-HRP) (BP0088), InVivoPlus rat IgG1 isotype control (BP0290)
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer (IP0070)
Additional information: 
Synonyms: C9B7W; BP0174; Lag3; Ly66; LAG-3; CD223; lymphocyte activation gene 3 protein; lymphocyte-activation gene 3; BioXCell
Rouhani SJ, Eccles JD, Riccardi P, et al. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. Nat Commun. 2015;6:6771. Read more
Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS ONE. 2014;9(11):e109080. Read more
Erickson JJ, Rogers MC, Hastings AK, Tollefson SJ, Williams JV. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol. 2014;193(10):5108-17. Read more
Verhagen J, Wraith DC. Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3⁺ Treg cells. J Immunol Methods. 2014;414:58-64. Read more
Mcgray AJ, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22(1):206-18. Read more
Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190(9):4899-909. Read more